Leadership Team

Doug Lawrence
Chief Executive Officer

Doug Lawrence is a 27-year veteran of the medical devices industry, with a diverse background in R&D, marketing, finance and general management roles. Mr. Lawrence has significant experience raising capital as well as financial management, operational experience, and extensive commercial expertise. As Chief Executive Officer, Mr. Lawrence is directly responsible for leading the company’s strategic initiatives, financing and capital management, and all commercial healthcare activities including the execution of the company’s go-to-market strategy as well as establishing distribution and sales channels that drive and expand commercial value.

Prior to joining RPS Diagnostics, Mr. Lawrence was the Chief Executive Officer at CeQur, a startup insulin patch pump company in Marlboro, MA, from 2014 to 2016. Prior to CEQUR, Mr. Lawrence was an executive at Becton Dickinson & Company, where he led the corporate point-of-care diagnostics initiative, and served as global Vice President for the company’s Insulin Injection business, where he led global launches of a number of insulin delivery innovations. Mr. Lawrence’s background includes medical device and pharmaceutical industry experience at category-leading companies including Procter & Gamble and Ohmeda/The BOC Group. Prior to his work at BD Diabetes Care, he was responsible for the development and launch of innovative products in ophthalmology, infusion therapy, critical care, and consumer health.

Mr. Lawrence has a degree in Systems Engineering from the University of Pennsylvania as well as business degrees from the University of Pennsylvania’s Wharton School and Northwestern University’s Kellogg School. He is Chairman Emeritus of the Massachusetts Medical Device Industry Council and Board Member at H2L Medical.

hor-rule

Robert Sambursky, MD

Robert Sambursky, MD
President and Chief Technology and Medical Officer

Robert Sambursky, MD is one of the original founders of RPS Diagnostics, and has served various roles including Chief Executive Officer from July 2012 until June 2017, President since 2010, and Chief Medical Officer since 2008. He is an inaugural member of both the Leadership Team and Board of Directors. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology, and infectious disease. He conceived numerous patents, developed a point-of-care (POC) diagnostic platform, designed clinical protocols, and served as the regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as both U.S. FDA 510(k) clearance and CLIA waiver designations. Further, Dr. Sambursky was responsible for all medical affairs activities including development of key opinion leaders (KOLs), clinical marketing and product training, and creating a successful reimbursement strategy that lead to the issuance of dedicated U.S. Medicare CPT codes.

Currently Dr. Sambursky continues to serve as President as well as Chief Technology and Medical Officer where his leadership responsibilities include strategic planning and business development, oversight of innovation, research and new product development, and leading clinical and regulatory affairs, KOL development, health policy and government affairs, reimbursement, and evidence based marketing. He is considered a subject area expert and serves as a global spokesperson.

In addition, Dr. Sambursky is a practicing, board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He currently sits on several ophthalmic pharmaceutical advisory boards, serves as an editorial consultant to several professional organizations and publications, is a member of the Vanguard Ophthalmology Society, and has co-authored numerous articles in medical journals. He currently serves as a consultant for Quidel Corp. Dr. Sambursky earned his BA in Biology from Brown University, MA in Medical Sciences with a concentration in biochemistry and microbiology from Boston University, and MD from Boston University School of Medicine. He completed his medical internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.

hor-rule

Peter J. Condon, PhD
Vice President of Technology

Peter Condon has managed research and product development (R&D) efforts in diagnostic and biotech start-up companies as well as in larger established organizations including Meridian Bioscience, Immunetics Inc., Formatech Inc., and Daktari Diagnostics. Condon has successfully developed a wide variety of diagnostic products for use in point-of-care and reference laboratory settings. Specifically, he has expertise in immunoassay and microfluidic product development as well as significant experience in product development from the concept stage through regulatory approval in the U.S. and Europe. In addition to his R&D responsibilities, Condon is currently providing oversight for quality and regulatory affairs. Condon earned his BA from Brown University and PhD from the University of Massachusetts.

hor-rule

Christopher Allen Michaels
Vice President of Strategic Development and Technology Licensing

Chris Michaels has more than 20 years of successful intellectual property law experience with Brown & Michaels, PC, where he has served as managing partner since 1994. Prior to joining RPS, his years of experience as RPS’s patent attorney and expertise in the biotechnology field facilitated an intimate knowledge and understanding of the RPS technology platform. At RPS, Michaels strengthens the company’s intellectual property position, assesses competitive landscapes, supports product pipeline partnership licensing, and assesses future technology out-licensing opportunities. He has also published articles in legal, patent, and technology journals and has edited several books on patent and trademark practice. Michaels earned his BA from Bucknell University, his JD from Syracuse University, an MBA at the University of Pennsylvania’s Wharton School and is currently working toward a Management Science and Engineering Graduate Certificate at Stanford University.

hor-rule

Kurt Phinney
Senior Director of Operations

Kurt Phinney has 15 years of experience leading biomedical project management and manufacturing. Phinney’s background includes development of biochemical assays (lateral flow, ELISA, western blot, and cell-based) with the State Laboratory Institute of Massachusetts, Immunetics, and Floria Biosystems. His ongoing pursuit of novel biotechnology has resulted in multiple patents and FDA clearances. Phinney also provided consultation to biotechnology, information technology, and pharmaceutical firms in the U.S. and overseas. Prior to this, he served as a Health Service Corpsman with the United States Coast Guard. Phinney received a BS in Biology from the State University of New York at Albany.